Managing Adverse Effects

Articles: 5

  • Switching from TDF/FTC to TAF/FTC

    Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...

  • Adult and Adolescent Guidelines: Major Changes

    The U.S. Department of Health and Human Services has released new treatment guidelines for adults and adolescents, and these contain some important changes. Key among these is a major shakeup in the "Recommended Regimen Options" for initial therapy. 

    Efavirenz/TDF/FTC (Atripla) has...
  • Efavirenz Updates: Bone Mineral Density & Suicidality

    Efavirenz and Bone Mineral Density

    Persons with HIV infection have a number of risk factors for decreased bone mineral density (BMD), related not just to effects of HIV or resulting illness but also to ART. For example, BMD decreases by as much as 5-6% after initiation of ART, and certain ARVs (...

  • Cobicistat and Stribild Use in Patients with Renal Insufficiency

    Coauthor: Susa Coffey, MD; Medical Editor, AETC National Resource Center

    An open-label study is evaluating the renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, or the "quad" pill) and cobicistat in patients with mild-to-moderate renal...

  • Winter 2011-12: ARV Fast Takes

    Rilpivirine Added to DHHS RecommendationsRaltegravir-Associated Skin ReactionsDarunavir Oral Suspension

    Rilpivirine Added to DHHS Recommendations

    Recommendations for use of the recently approved NNRTI rilpivirine have been added to the U.S. Department of Health and Human Services adult and...

Day Title
10/23
Infectious Diseases Society of America: ID Week 2016